ClinicalTrials.gg
CompletedNCT06890611Updated Oct 9, 2025

A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants

A Phase 1 interventional study of Bimagrumab and Tirzepatide in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-09.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

The main purpose of this study is to evaluate the body concentration of different forms of bimagrumab, administered alone or with tirzepatide. Participation in the study will last about 4.5 months, including screening and follow-up.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are considered healthy as determined by medical evaluation including medical history and physical examination
  • Have a (BMI) within the range of 22.0 to 30.0 kilograms per square meter (kg/m2), inclusive

Exclusion criteria

Exclusion Criteria:

  • Have current or a history of pancreatitis or hepatitis
  • Have a self-reported increase or decrease in body weight, greater than 5 kilograms (kg), within 3 months prior to screening
  • Have uncontrolled high blood pressure
  • Have taken medications or alternative remedies to promote weight loss within 3 months prior to screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    Bimagrumab Dose 1 Reference Material

    Participants will receive a single dose of bimagrumab subcutaneously (SC)

    Drug: Bimagrumab

  • Experimental
    Bimagrumab Dose 1 Test Material + Tirzepatide (Coadministration)

    Participants will receive a single dose of bimagrumab SC and a single dose of tirzepatide SC

    Drug: Bimagrumab · Drug: Tirzepatide

  • Experimental
    Bimagrumab Dose 1 Test Material + Tirzepatide (Coformulation)

    Participants will receive a single dose of bimagrumab with tirzepatide SC

    Drug: Bimagrumab + Tirzepatide Coformulation

  • Experimental
    Bimagrumab Dose 2 Test Material + Tirzepatide (Coadministration)

    Participants will receive bimagrumab SC and tirzepatide SC for 4 weeks

    Drug: Bimagrumab · Drug: Tirzepatide

  • Experimental
    Bimagrumab Dose 2 Test Material + Tirzepatide (Coformulation)

    Participants will receive bimagrumab with tirzepatide SC for 4 weeks

    Drug: Bimagrumab + Tirzepatide Coformulation

Interventions

  • Administered SC

    Also known as: LY3985863, BYM338, VER201

  • Administered SC

    Also known as: LY3298176

  • DrugBimagrumab + Tirzepatide Coformulation

    Administered SC

    Also known as: LY900042

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Bimagrumab Test Material

    Time frame: Predose through Week 13

  2. PK: Cmax of Bimagrumab Reference Material

    Time frame: Predose through Week 13

  3. PK: Cmax of Bimagrumab Coadministered with Tirzepatide

    Time frame: Predose through Week 13

  4. PK: Cmax of Tirzepatide Coadministered with Bimagrumab

    Time frame: Predose through Week 16

  5. PK: Cmax of Bimagrumab Coformulated with Tirzepatide

    Time frame: Predose through Week 16

  6. PK: Cmax of Tirzepatide Coformulated with Bimagrumab

    Time frame: Predose through Week 16

  7. PK: Area Under the Curve from Zero to Infinity AUC (AUC(0-∞)) of Bimagrumab Test Material

    Time frame: Predose through Week 13

  8. PK: AUC(0-∞) of Bimagrumab Reference Material

    Time frame: Predose through Week 13

  9. PK: AUC(0-∞) of Bimagrumab Coadministered with Tirzepatide

    Time frame: Predose through Week 13

  10. PK: AUC(0-∞) of Tirzepatide Coadministered with Bimagrumab

    Time frame: Predose through Week 16

  11. PK: AUC(0-∞) of Bimagrumab Coformulated with Tirzepatide

    Time frame: Predose through Week 16

  12. PK: AUC(0-∞) of Tirzepatide Coformulated with Bimagrumab

    Time frame: Predose through Week 16

07

Study locations

1 site
  • Fortrea Clinical Research Unit
    Dallas, Texas 75247, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2025 to primary completion in Sep 2025, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2025
First posted
Mar 24, 2025
StartActual
Mar 25, 2025
Primary completionActual
Sep 26, 2025
CompletionActual
Sep 26, 2025
Last update
Oct 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06890611
Responsible party
Sponsor
First posted
Mar 24, 2025
Start date
Mar 25, 2025
Primary completion
Sep 26, 2025
Completion
Sep 26, 2025
Last update
Oct 9, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimagrumab

Start the discussion